11 terminated. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Terminated 11 |
| Phase 2 | 1 | Terminated 1 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Ustekinumab, Placebo, Glucorticoid Taper Regimen - Takayasu Arteritis | Phase 3 | Terminated | Janssen Pharmaceutical K.K. | 14 | 2021-09-15 | 2025-04-29 |
| Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis Colchicine - IgA Vasculitis | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 27 | 2019-11-12 | 2026-11-06 |
| Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA Sarilumab SAR153191, Sarilumab matching placebo, Prednisone - Giant Cell Arteritis | Phase 3 | Terminated | Sanofi | 83 | 2018-11-20 | 2022-03-28 |
| Giant Cell Arteritis and Anakinra Trial PLACEBO, ANAKINRA - Giant Cell Arteritis | Phase 3 | Terminated | University Hospital, Caen | 30 | 2017-05-11 | 2026-04-02 |
| Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Sirukumab, Placebo to match sirukumab, Prednisone - Giant Cell Arteritis | Phase 3 | Terminated | GlaxoSmithKline | 161 | 2015-10-16 | 2019-07-31 |
| Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis Placebo, Gevokizumab - Behcet's Disease Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 4 | 2014-11-01 | 2015-12-29 |
| Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids - Wegeners Granulomatosis | Phase 3 | Terminated | Nordic Pharma SAS | 4 | 2011-11-01 | 2015-05-29 |
| GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases depot leuprolide acetate 3.75 mg, Placebo - Lupus Erythematosus, Systemic, Systemic Vasculitis | Phase 3 | Terminated | Joseph Mccune | 14 | 2011-05-01 | 2017-06-27 |
| IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Cyclophosphamide, Mycophenolate mofetil, Azathioprine - ANCA Associated Systemic Vasculitis Including Wegener's, Granulomatosis and Microscopic Polyangiitis and | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 160 | 2003-05-01 | 2006-04-10 |
| Intravenous Immunoglobulin After Relapse in Vasculitis Intravenous immunoglobulins (human immunoglobulins G) - ANCA + Vasculitides Relapsing Either Under Corticosteroid, and Immunosuppressant Therapies or After One Year | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 40 | 2001-03-01 | 2006-05-22 |
| Plasma Exchange for Renal Vasculitis Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone - Wegener's Granulomatosis, Microscopic Polyangiitis | Phase 2 / Phase 3 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 150 | 1995-03-01 | 2011-08-03 |
Giant Cell Arteritis (3) · Granulomatosis with Polyangiitis (2) · Microscopic Polyangiitis (2) · Recurrence (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Behcet Syndrome (1) · IgA Vasculitis (1) · Lupus Erythematosus, Systemic (1) · Systemic Vasculitis (1) · Takayasu Arteritis (1) · Uveitis (1)
Cardiovascular Diseases (11) · Skin and Connective Tissue Diseases (11) · Vascular Diseases (11) · Skin Diseases (10) · Skin Diseases, Vascular (10) · Immune System Diseases (9) · Autoimmune Diseases (8) · Brain Diseases (5) · Central Nervous System Diseases (5) · Cerebrovascular Disorders (5) · Nervous System Diseases (5) · Arteritis (4) · Systemic Vasculitis (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3)
Prednisone (3) · Azathioprine (2) · Colchicine (1) · Cyclophosphamide (1) · Glucocorticoids (1) · Immunoglobulins, Intravenous (1) · Interleukin 1 Receptor Antagonist Protein (1) · Leuprolide (1) · Methotrexate (1) · Methylprednisolone (1) · Mycophenolic Acid (1) · Plasma Exchange (1) · Ustekinumab (1) · gevokizumab (1) · gusperimus (1)
Assistance Publique - Hôpitaux de Paris (3) · Cambridge University Hospitals NHS Foundation Trust (1) · GlaxoSmithKline (1) · Janssen Pharmaceutical K.K. (1) · Joseph Mccune (1) · Nordic Pharma SAS (1) · Sanofi (1) · University Hospital, Caen (1) · XOMA (US) LLC (1)
France (6) · United Kingdom (4) · United States (4) · Australia (2) · Belgium (2) · Germany (2) · Hungary (2) · Italy (2) · Netherlands (2) · Spain (2) · Argentina (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Czechia (1)
David Jayne, MD (1) · Niels Rasmussen, MD (1) · William J McCune, M.D. (1)
PMID 18163506, PMID 21060104, PMID 23615499, PMID 28592297, PMID 32844378, PMID 37840134, PMID 39400109, PMID 40104212, PMID 40483523
2015 (1), 2017 (1), 2018 (1), R01HD066139 (1)